BeOne Medicines Ltd. - Sponsored ADR (ONC) reported $1.32 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 41.6%. EPS of $0.84 for the same period compares to -$1.15 a year ago.
The reported revenue represents a surprise of +6.17% over the Zacks Consensus Estimate of $1.24 billion. With the consensus EPS estimate being $0.48, the EPS surprise was +75%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how BeOne Medicines Ltd. - Sponsored ADR performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product Revenue- BRUKINSA(Zanubrutinib): $949.84 million compared to the $913.66 million average estimate based on five analysts.
- Revenues- Product Revenue- TEVIMBRA: $193.52 million compared to the $179.91 million average estimate based on five analysts.
- Revenues- Product revenue, net: $1.3 billion versus the four-analyst average estimate of $1.24 billion. The reported number represents a year-over-year change of +41.4%.
- Revenues- Collaboration revenue: $13.22 million versus $7.59 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +64.9% change.
- Revenues- Product Revenue- KYPROLIS: $19.42 million versus $18.48 million estimated by three analysts on average.
- Revenues- Product Revenue- BLINCYTO: $25.59 million versus $25.54 million estimated by three analysts on average.
- Revenues- Product Revenue- POBEVCY: $11.24 million versus the three-analyst average estimate of $12.15 million.
- Revenues- Product Revenue- Other: $21.15 million compared to the $16.1 million average estimate based on three analysts.
- Revenues- Product Revenue- XGEVA: $81.32 million versus $66.49 million estimated by three analysts on average.
View all Key Company Metrics for BeOne Medicines Ltd. - Sponsored ADR here>>>
Shares of BeOne Medicines Ltd. - Sponsored ADR have returned +25.7% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BeOne Medicines Ltd. - Sponsored ADR (ONC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
